Check out today’s featured companies who have recently raised a round of funding, and be sure to check out the full list of past healthcare IT fundings.
Clairity Raises $43 Million in Series B to Launch First FDA-Authorized AI Platform for Breast Cancer Risk Prediction
Clairity, Inc., an AI-driven precision health company pioneering image-based risk prediction, today announced the closing of a $43 million Series B financing. The funds will be used to commercialize the company’s product, Clairity Breast, the first FDA-authorized artificial intelligence platform that predicts a woman’s five-year risk of breast cancer directly from a routine mammogram, and to advance development of Clairity Breast 3D and Clairity Heart, Clairity’s next offering focused on predicting cardiovascular risk from the same routine imaging exam.
The round was led by ACE Global Equity and Santé Ventures, with continued participation from the Breast Cancer Research Foundation (BCRF) and several new investors. The strong commitment from the syndicate reflects broad confidence in Clairity’s mission to transform how breast cancer is found, managed, and ultimately prevented, and in the power of the company’s AI platform to extend into other areas of population health.
The new funding will allow Clairity to accelerate U.S. commercialization, expand partnerships with leading imaging centers and health systems, and drive continued development of Clairity’s broader predictive health platform.
Following the successful FDA authorization of Clairity Breast and its initial rollout to marquee health systems, the company is expanding its pipeline to include new AI-based predictive offerings for other major diseases, leveraging the same deep learning framework on which Clairity Breast was built…
Full release here, originally announced November 13th, 2025.
Healthcare AI Company No Barrier Raises $2.7M to Eliminate Language Barriers with Real-Time, Compliant AI Interpretation
No Barrier, the leader in AI-powered medical translation redefining language access in healthcare, today announced an oversubscribed $2.7 million Seed Round led by A-Squared Ventures, Esplanade Ventures, Rock Health Capital, and Fusion.
No Barrier’s AI-powered, real-time language interpretation technology integrates into existing clinician workflows, improving providers’ and health systems’ limited-English-proficiency (LEP) services to the highest quality with zero-wait access. Unlike generic AI translators, No Barrier’s solution is purpose-built for healthcare — seamlessly integrating into clinical systems with HIPAA-grade security and EHR workflow support.
This new funding accelerates expansion across all points of care – from appointment check-in to treatment plans – ensuring language access throughout every patient journey.
Over 25.7 million Americans have limited English proficiency, creating critical communication barriers that delay diagnoses and increase readmissions…
Full release here, originally announced November 17th, 2025.
House Rx Raises $55 Million to Scale In-Clinic Specialty Pharmacy Model
House Rx, a health tech company focused on making specialty medications more accessible and affordable for patients, today announced it has raised $55 million in Series B equity and debt to expand its in-clinic specialty pharmacy model. The financing was led by New Enterprise Associates (NEA) and Town Hall Ventures and included participation from LRVHealth, First Round Capital, Bessemer Venture Partners, and Silicon Valley Bank. This new investment brings the company’s total capital raised to date to $100 million.
At a time when regulators and states are actively challenging the Pharmacy Benefit Manager (PBM)-owned, closed network specialty pharmacy model, House Rx offers an alternative vision – a nationwide network of locally owned, brick-and-mortar specialty dispensaries embedded in specialty clinics. The model puts patients and providers at the center and delivers vastly superior quality outcomes. By partnering with specialty clinics to integrate pharmacy services directly into care delivery, House Rx enables providers to offer high-touch, local alternatives to centralized pharmacy fulfillment models. This approach improves coordination between providers and pharmacists, reduces administrative complexity, and delivers better outcomes for patients dealing with complex conditions.
“There’s finally momentum behind creating a specialty pharmacy system that makes it easier for patients to seamlessly and more affordably access the medications they desperately need,” said Ogi Kavazovic, Founder and CEO at House Rx. “We’re seeing interest from stakeholders across the healthcare system — healthcare providers, manufacturers, payers, investors, and certainly employees who all recognize the opportunity to finally challenge the status quo in specialty pharmacy. We all want to do better by patients and help bring down the overwhelming expense to our healthcare system. With the support of this funding, we’re ready to scale operations to meet the exploding demand.”
To date, House Rx has partnered with more than 1,000 providers at 80 clinic sites nationwide, helping them stand up and successfully operate in-house pharmacies that deliver better outcomes for patients…
Full release here, originally announced November 12th, 2025.
No comments:
Post a Comment